| Literature DB >> 24614248 |
Seon Joo Park1, Hyun Seok Song2, Oh Seok Kwon3, Ji Hyun Chung4, Seung Hwan Lee4, Ji Hyun An5, Sae Ryun Ahn4, Ji Eun Lee6, Hyeonseok Yoon6, Tai Hyun Park7, Jyongsik Jang5.
Abstract
The development of molecular detection that allows rapid responses with high sensitivity and selectivity remains challenging. Herein, we demonstrate the strategy of novel bio-nanotechnology to successfully fabricate high-performance dopamine (DA) biosensor using DA Receptor-containing uniform-particle-shaped Nanovesicles-immobilized Carboxylated poly(3,4-ethylenedioxythiophene) (CPEDOT) NTs (DRNCNs). DA molecules are commonly associated with serious diseases, such as Parkinson's and Alzheimer's diseases. For the first time, nanovesicles containing a human DA receptor D1 (hDRD1) were successfully constructed from HEK-293 cells, stably expressing hDRD1. The nanovesicles containing hDRD1 as gate-potential modulator on the conducting polymer (CP) nanomaterial transistors provided high-performance responses to DA molecule owing to their uniform, monodispersive morphologies and outstanding discrimination ability. Specifically, the DRNCNs were integrated into a liquid-ion gated field-effect transistor (FET) system via immobilization and attachment processes, leading to high sensitivity and excellent selectivity toward DA in liquid state. Unprecedentedly, the minimum detectable level (MDL) from the field-induced DA responses was as low as 10 pM in real- time, which is 10 times more sensitive than that of previously reported CP based-DA biosensors. Moreover, the FET-type DRNCN biosensor had a rapid response time (<1 s) and showed excellent selectivity in human serum.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24614248 PMCID: PMC3949245 DOI: 10.1038/srep04342
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic illustrations of construction steps for DRNCN geometry.
Figure 2Construction of stable cell-line expressing hDRD1 and nanovesicles.
(a) Optical and fluorescence image of HEK-293 cells stably expressing hDRD1 (scale bar: 50 μm). (b) Ca2+ signaling assay of HEK293 cells stably expressing hDRD1 upon various concentrations of DA. (c) Western blot analysis of each membrane fractions of cells and nanovesicles expressing hDRD1 using anti-HA antibody (M: marker, C: cells and V: nanovesicles). (d) SEM image of nanovesicles derived from HEK-293 cells stably expressing hDRD1. (e) Real-time measurement of Ca2+ influx into nanovesicles containing hDRD1 upon the addition of 1 mM dopamine.
Figure 3Characterization of sensing substrate.
(a) XPS spectra of the IMA substrate before and after aminosilane treatment. (b) XPS N 1s spectrum of aminosilane-treated IMA substrate. (c) XPS C 1s spectrum of the CPEDOTs.
Figure 4FE-SEM images before (a) and after (b) the introduction of the nanovesicles on CPEDOT NTs.
Figure 5(a) Current-voltage (I-V) curves of the IMA surface-attached CPEDOT before and after the immobilization of nanovesicles. (b) Schematic illustration of the liquid-ion gated FET-type DA biosensor using DRNCN. (c) Output curves of DRNCN FET (V was from −0.1 to −1 V in a step of −0.1 V and Vds scan rate was −5 mV s−1).
Figure 6(a) Real-time responses with normalized current changes (ΔI/I0) and (b) calibration curves of DRNCN toward various DA concentrations (S indicates the normalized current change). (c) Selective responses of the DA biosensor using DRNCN toward non-target neurotransmitters (PBS, 1 mM Serotonin, and 1 mM Epinephrine) and dopamine (10 pM DA).
Figure 7Selective response of FET-type DRNCN biosensor toward DA molecules in human serum.